Liquid pharmaceutical formulations of omeprazole or esomeprazole
By combining liquid drugs in the range of 7.5 to 9.5 pH, the problem of omeprazole degradation in acidic environments and the preparation of solid suspensions is solved, and a stable and easy-to-take omeprazole preparation is provided, suitable for gastric acid Treatment of related diseases.
Patent Information
- Application Number
- CN202380026924.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-18
- Filing Date
- 2023-03-16
- Publication Date
- 2024-11-08
AI Technical Summary
The existing omeprazole preparations have stability problems, especially rapid degradation in acidic environments, and solid suspensions need to be strictly prepared, making them difficult to mass produce and take, and cannot meet the needs of patients who cannot swallow or are unwilling to take capsules.
A combination of a non-aqueous liquid containing substituted benzimidazole and a polar aprotic solvent and an aqueous liquid of a base is provided to form a combined liquid drug in the range of 7.5 to 9.5 pH for oral treatment of gastric acid-related diseases.
The stability and rapid absorption of omeprazole are achieved, the degradation of gastric acid is avoided, and the liquid preparation is easy to prepare and take, suitable for adults and children, and has a long storage period.
Smart Images

Figure CN118922175A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a two-part pharmaceutical formulation comprising a substituted benzimidazole, more particularly esomeprazole. The invention also relates to the preparation of such a pharmaceutical formulation. Background of the Invention
[0003] Proton pump inhibitors are a class of drugs whose primary effect is to significantly and permanently reduce the production of gastric acid. They have the general structure (I)
[0004]
[0005] name <![CDATA[R 1 ]]> <![CDATA[R 2 ]]> <![CDATA[R 3 ]]> <![CDATA[R 4 ]]> <![CDATA[R 5 ]]> X Timoprazol H H H H H CH Omeprazole <![CDATA[OCH3]]> H <![CDATA[CH3]]> <![CDATA[OCH3]]> <![CDATA[CH3]]> CH Lansoprazole H H <![CDATA[CH3]]> <![CDATA[OCH2CF3]]> H CH Pantoprazole <![CDATA[CF2HO]]> H <![CDATA[OCH3]]> <![CDATA[OCH3]]> H CH Rabeprazole H H <![CDATA[CH3]]> <![CDATA[O(CH2)3OCH3]]> H CH Tenoprazole <![CDATA[OCH3]]> H <![CDATA[CH3]]> <![CDATA[OCH3]]> <![CDATA[CH3]]> N Picoprazole <![CDATA[CH3]]> <![CDATA[CO2CH3]]> <![CDATA[CH3]]> H H CH
[0006] In addition, certain compounds shown in the table are used as single enantiomers (at the chiral center indicated as * in formula (I)). Esomeprazole is a single enantiomer of omeprazole. Dexlansoprazole is a single enantiomer of lansoprazole.
[0007] Omeprazole is a substituted benzimidazole, 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole, which irreversibly inhibits the secretory surface H + / K + ATPase (proton pump) to reduce gastric acid production. The chemical formula of omeprazole is
[0008]
[0009] The proton pump is directly responsible for converting H + Ions are secreted into the gastric lumen. By inhibiting the proton pump, omeprazole modulates the final step of hydrogen ion production in the gastric acid secretion pathway in the gastrointestinal tract of mammals.
[0010] Omeprazole and other proton pump inhibitors (PPIs) are used to treat a variety of conditions that require reduction of acid production through proton pump inhibition, such as gastritis, gastroesophageal reflux disease (GERD), dyspepsia, peptic ulcer disease, laryngopharyngeal reflux, gastric and duodenal ulcers, and Zollinger-Ellison syndrome.
[0011] Typically, omeprazole is formulated as tablets or capsules for oral administration. However, such formulations are problematic for patients who may be unable and / or unwilling to swallow capsules or tablets. This form is also undesirable for pediatric use.
[0012] Liquid formulations of omeprazole for oral administration have proven to be problematic due to the unstable nature of the active ingredient. Omeprazole is an acid-labile compound and therefore rapidly degrades in acidic conditions such as those found in the stomach. Omeprazole is known to degrade in an environment with a pH below 4.0 with a half-life of less than 10 minutes; at pH 6.5, the half-life is 18 hours, and at pH 11 is about 300 days.
[0013] An alternative to the above formulation is to provide omeprazole as a solid suspension, wherein particles of omeprazole are mixed with a suitable carrier. The suspension needs to be prepared immediately before use, and the manner in which it is prepared requires strict control. Therefore, it is possible that the drug may become ineffective if not prepared correctly. Some patients also find that the suspension is very unpleasant to take. Omeprazole formulated as a suspension has a very short shelf life and it is also difficult to prepare them in bulk.
[0014] One solution is to provide a liquid suspension of omeprazole that does not require controlled preparation. However, such suspensions need to have high viscosity to ensure that the microparticles of omeprazole are fully suspended in the solution. This high viscosity makes it difficult to measure the correct dose. Such preparations also provide a slow release of omeprazole, so they are limited in use.
[0015] It would therefore be desirable to provide stable pharmaceutical formulations comprising omeprazole or other PPIs and which also address the problems identified above.
[0016] The present invention relates to a pharmaceutical formulation comprising omeprazole, esomeprazole or other proton pump inhibitors or mixtures thereof, which provides a cost-effective method for treating the aforementioned conditions and is convenient to prepare. It also provides an alternative for patients who are unable and / or unwilling to take capsules. The present formulation is stable, easily soluble and allows for immediate release and rapid absorption of the therapeutic agent without being degraded by gastric acid.
[0017] US2009 / 048322 relates to a drug delivery system comprising a benzimidazole derivative, an oil, a surfactant, a co-surfactant and a dipolar aprotic solvent in a microemulsion formulation. The formulation appears to be suitable for pulmonary delivery.
[0018] WO 2003 / 086392 A2 relates to orally deliverable finely divided self-emulsifiable pharmaceutical compositions comprising a poorly water-soluble drug, namely a cyclooxygenase-2 inhibiting drug, more particularly to such compositions wherein the drug is in dissolved form, and to processes for preparing such compositions.
[0019] CA2934538 A1 relates to a method of preparing a pharmaceutical solution comprising a therapeutic agent. It further relates to a dry pharmaceutical composition (eg, a dry powder composition) that can be rapidly dissolved and / or reconstituted for delivery to a patient.
[0020] The present invention solves the problems associated with the prior art. SUMMARY OF THE INVENTION
[0022] According to a first aspect, the present invention provides a pharmaceutical formulation comprising:
[0023] a first composition which is a non-aqueous liquid comprising a substituted benzimidazole and a polar aprotic solvent; and
[0024] a second composition which is an aqueous liquid comprising a base;
[0025] Therein, the first and second compositions are configured to be combined prior to use to provide a combined liquid medicament having a pH in the range between 7.5 and 9.5.
[0026] According to another aspect, the pharmaceutical formulation of the invention is provided for use as a medicament for treating a condition selected from the group consisting of gastritis, gastroesophageal reflux disease, dyspepsia, peptic ulcer disease, laryngopharyngeal reflux, gastric and duodenal ulcers or Zollinger-Ellison syndrome.
[0027] According to another aspect, a kit is provided comprising: a first compartment comprising a first composition as defined herein; a second compartment comprising a second composition as defined herein; wherein the first and second containers are adapted to allow liquid communication therebetween upon activation to form a combined liquid medicament as defined herein.
[0028] According to another aspect, there is provided a method of treating a condition selected from the group consisting of gastritis, gastroesophageal reflux disease, dyspepsia, peptic ulcer disease, laryngopharyngeal reflux, gastric and duodenal ulcers or Zollinger-Ellison syndrome in a patient in need thereof, comprising mixing a first composition as defined herein and a second composition as defined herein and administering the combined liquid medication to the patient. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 A two-part container suitable for storing a pharmaceutical formulation according to the invention is shown. DETAILED DESCRIPTION OF THE INVENTION
[0031] According to the present invention, there is provided a two-part pharmaceutical formulation comprising a first and a second composition, wherein the first composition is a non-aqueous liquid comprising a substituted benzimidazole and a polar aprotic solvent, and the second composition is an aqueous liquid comprising a base, wherein the two compositions are combined to obtain a combined liquid medicament for oral use.
[0032] In a preferred embodiment, the substituted benzimidazole is selected from the group of proton pump inhibitors. Proton pump inhibitors are preferably one of those defined in the above-mentioned formula (I), including pharmaceutically acceptable salts, esters and enantiomeric mixtures thereof. More preferably, the therapeutic agent is selected from the group consisting of: omeprazole, esomeprazole, lansoprazole, right lansoprazole, timoprazole, picoprazole, pantoprazole, rabeprazole and tenatoprazole. These proton pump inhibitors can be used alone or in combination with each other. These inhibitors block the hydrogen / potassium adenosine triphosphatase system (HTP) of gastric parietal cells. + / K + ATPase) provides a long-lasting reduction in gastric acid production.
[0033] Preferably, the therapeutic agent is selected from omeprazole, esomeprazole, pantoprazole and pharmaceutically acceptable salts, enantiomers, alkaline salts, enantiomers, hydrates or derivatives thereof. In a preferred embodiment, the therapeutic agent is omeprazole or a pharmaceutically acceptable salt. The pharmaceutically acceptable salt of the therapeutic agent can include alkali metal salts such as sodium, lithium and potassium salts. The pharmaceutically acceptable salt of the therapeutic agent can also include alkaline earth and transition metal salts such as calcium and magnesium salts. Particularly preferred are metal salts of esomeprazole, particularly esomeprazole sodium.
[0034] The therapeutic agent is present in the first composition at a concentration of between about 10 mg / ml and about 200 mg / ml. Preferably, the amount of the therapeutic agent in the first composition may be between about 50 mg / ml and about 100 mg / ml. More preferably, the therapeutic agent is at a concentration of about 70 mg / ml. The therapeutic agent has been found to be stable in polar aprotic solvents at these concentrations.
[0035] Preferably, the first composition is present in an amount of 1 to 5 mL, preferably about 2 mL. Preferably, the second composition is present in an amount of 25 to 100 mL, preferably about 68 mL.
[0036] The therapeutic agent can be present in the first composition in any suitable form, such as in the form of a suspension, liquid, solution, powder, granule, dry powder, dry granule or microgranule. The therapeutic agent can additionally be provided with a coating, such as, for example, an enteric coating, which will be stable against degradation when in contact with an acidic medium (such as present in the stomach), but will rapidly decompose at a higher pH when absorbed in the gastrointestinal tract. In a preferred embodiment, the therapeutic agent is provided in the form of a liquid, preferably a solution.
[0037] As used herein, the term "polar aprotic solvent" refers to a solvent that lacks acidic protons and is polar. Preferably, the polar aprotic solvent is miscible with water. Preferably, the polar aprotic solvent is a sulfur-containing solvent. Most preferably, the polar aprotic solvent is dimethyl sulfoxide (DMSO).
[0038] The second composition of the present invention comprises a diluent and a base. The diluent can be any suitable liquid aqueous diluent, for example, water, or a mixture of one or more solvents comprising water. Preferably, the diluent is water. The amount of the diluent depends on the final volume of the desired preparation, which depends on the concentration of the therapeutic agent.
[0039] The second composition of the present invention may contain one or more pharmaceutically acceptable excipients and / or adjuvants. These are preferably selected from one or more of the group consisting of: viscosity building agents, dispersants, emulsifiers, stabilizers, preservatives, defoamers, flavoring agents, antioxidants, chelating agents and tension regulators.
[0040] Tackifier
[0041] Viscosity enhancers (or thickeners) are used to adjust the viscosity of the formulation and reduce the bitterness of the active pharmaceutical ingredient. The amount of thickener depends on the viscosity required for the final formulation and / or therapeutic agent. The DV2T RV viscometer is used for apparent viscosity measurement in the present invention. In a preferred embodiment, the viscosity of the final pharmaceutical formulation (combined solution) of the present invention can be from about 200 centipoise to about 600 centipoise. In a preferred embodiment, the viscosity of the final formulation is from about 300 centipoise to about 400 centipoise. The viscosity of the first composition can be from about 150 centipoise to about 450 centipoise, or from about 200 centipoise to about 300 centipoise. The viscosity of the second composition can be from about 350 centipoise to about 650 centipoise, or from about 400 centipoise to about 550 centipoise. The thickener can be selected from carageenan, powdered cellulose, sodium alginate, methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose / microcrystalline cellulose mixture, ion exchange cross-linked polyacrylic acid polymer, polysaccharide, starch, carbomer or a mixture thereof. In a preferred embodiment, the thickener is a combination of a polysaccharide and sodium carboxymethylcellulose. Xanthan gum is preferred.
[0042] Emulsifier
[0043] Emulsifiers are used to put the second composition in a stable emulsion form. Emulsifiers are preferably selected from polyglycerol esters, polysorbates, monoglycerides and diglycerides of fatty acid esters, phosphatidylcholine (lecithin) and polyoxyethylene derivatives of sorbitan fatty acid esters. Preferred emulsifiers have a hydrophilic-lipophilic balance (HLB) greater than 8 in the case of water-based diluents / second compositions, and less than 8 in the case of emulsion diluents / second compositions. The hydrophilic-lipophilic balance (HLB) can be evaluated by the method of Davies Proceedings of the International Congress of Surface Activity, 1957, pp.426-38, which is incorporated herein by reference. Preferred emulsifiers are selected from polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, polyoxyglycerol esters of sorbitan monooleate, phosphatidylcholine, polyglyceryl-3 oleate and mixtures thereof.
[0044] Stabilizer
[0045] Stabilizers are added to the second composition to prevent aggregation. Stabilizers are preferably selected from PVP (povidone), PVA (polyvinyl alcohol), PEG (polyethylene glycol), HPMC (hydroxypropyl methylcellulose), HPC (hydroxypropyl cellulose), HEC (hydroxyethyl cellulose), NaCMC (sodium carboxymethyl cellulose), SD (docusate sodium), SLS (sodium lauryl sulfate), PEI (polyethylene imine), TPGS (D-α-tocopheryl polyethylene glycol succinate), PEO (polyethylene oxide) and PPO (polypropylene oxide), amino acids (preferably arginine, cysteine and / or glycine), poloxamers and mixtures thereof. Preferred stabilizers are selected from amino acids (preferably arginine, cysteine and / or glycine), poloxamers and mixtures thereof. Poloxamer 407 (BASF trade name Kolliphor P ).
[0046] preservative
[0047] The preservative is used to preserve the second composition to prevent decomposition and microbial growth. The preservative can be a quaternary ammonium compound (such as benzalkonium chloride (BAC), didecyldimethylammonium chloride (DDAC)), a paraben, butylated hydroxytoluene, butylated hydroxyanisole, tert-butylhydroquinone EDTA, disodium EDTA or its salt; sugar alcohols such as glycerol and sorbitol; polyoxyethylene 20 sorbitan monooleate such as polysorbate 80, polyoxyethylene 20 sorbitan monolaurate such as polysorbate 20; disodium phosphate; or a mixture thereof.
[0048] Preferred preservatives are selected from quaternary ammonium compounds, parabens, butylated hydroxytoluene, butylated hydroxyanisole, tert-butylhydroquinone and mixtures thereof. The preservative may be from about 0.01% (w / v) to about 2% (w / v), more preferably about 0.1% (w / v).
[0049] Defoaming agent
[0050] Defoamers prevent the formation of any bubbles or foam. Suitable defoamers can be selected from silicone-based defoamers such as dimethicone or its emulsions or suspensions, and non-silicone defoamers such as polypropylene polyether dispersions, castor oil, fatty alcohol esters, glycerides and mixtures thereof. A preferred defoamer is dimethicone. The defoamer is preferably present in an amount of 0.05% to 0.5% (w / v).
[0051] Flavoring
[0052] Sweeteners and flavorings are used to mask the bitter taste of active pharmaceutical ingredients, thereby providing preparations with good palatability and acceptability. Suitable sweeteners for the present invention are sugar, sugar alcohols, saccharin sodium, aspartame, acesulfame potassium, stevia, sodium cyclamate, propylene glycol, licorice extract, glycyrrhizin, maple extract and locust bean extract. Suitable flavorings can be selected from masking sweet flavors, sucralose, menthol (mint), lemon, orange, peach, cinnamon, black currant, cherry and chocolate flavor. Sweeteners and flavorings can exist in an amount of about 1.0% (w / v) to about 0.01% (w / v). More preferably, these sweeteners and flavorings can exist in an amount of about 0.25% (w / v), 0.2% (w / v), 0.15% (w / v) or 0.015% (w / v).
[0053] Antioxidants
[0054] Suitable antioxidants for the second composition are selected from ascorbic acid derivatives, thiol derivatives, sulfites, sodium sulfate, synthetic hindered phenols such as propyl gallate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), natural hindered phenols such as tocopherol, or mixtures thereof. Antioxidants provide stability and prevent oxidative degradation for the therapeutic agent. The amount of the antioxidant in the composition can be from about 0.05% (w / v) to about 0.5% (w / v) of the first composition, preferably from about 0.1% (w / v) to about 0.3% (w / v). However, it is preferred that there is no antioxidant.
[0055] Tonicity regulator
[0056] The purpose of the tension regulator (osmotic agent) used in the present invention is to provide the combined formulation with an osmotic pressure in the range of about 1000 to about 3000mOsmol / kg. In a preferred embodiment, the osmotic pressure can be about 1000 to about 1500mOsmol / kg or about 1500 to about 2500mOsmol / kg or about 1500 to about 2200mOsmol / kg. The presence of an osmotic agent ensures that the pharmaceutical preparation obtained has acceptable hypertonicity within the range so that the preparation can be taken in undiluted form. The osmotic agent can be selected from dextrose, mannitol, sorbitol, glycerol, sodium chloride and sodium sulfate or a combination thereof.
[0057] In the context of the present invention, base is used to adjust the pH of the preparation. Therefore, the base can change the pH of the final (i.e., the first and second compositions of the combination) preparation to obtain the desired pH that prevents the therapeutic agent form from being degraded by acidic gastric juice, and is suitable for oral administration. In a preferred embodiment, the pH of the final preparation (combined solution) is between 7.5 and 9.5. In a more preferred embodiment, the pH of the final preparation is between 8 and 9. In a more preferred embodiment, the pH of the combined solution is between 8.5 and 9. In a more preferred embodiment, the pH of the combined solution is about 9. The base can be selected from alkali metal or alkaline earth metal carbonates or bicarbonates, alkali metal or alkaline earth metal hydroxides, alkali metal or alkaline earth metal oxides, alkali metal or alkaline earth metal phosphates, citrates, acetates, and mixtures thereof. Preferably, the base is potassium bicarbonate.
[0058] The base ensures that when the first and second compositions are mixed, the combined medication is brought back into an acceptable range so that the pH of the combined liquid medication is consistent and stable upon administration.
[0059] The therapeutic agent used in the present invention is preferably slightly soluble in water at pH 7. In some embodiments, the second composition comprises a cosolvent in the present invention to improve the solubility of the active pharmaceutical ingredient in the combined formulation. The solvent and cosolvent can be selected from glycerol, sorbitol, propylene glycol, ethanol, polyethylene glycol or a mixture thereof. In a preferred embodiment, the solvent and cosolvent can be a sugar alcohol. The solvent and cosolvent can be present in an amount of about 5% (w / v) to about 20% (w / v), more preferably about 10% (w / v) to about 15% (w / v).
[0060] The function of a dispersant is to help slightly soluble ingredients dissolve properly. Suitable dispersants for use in the present invention are glycerol, sorbitol, propylene glycol, polyethylene glycol, ethanol and combinations thereof.
[0061] Preferably, both the first and second compositions are provided in the form of solutions.In a more preferred embodiment, the combined liquid medicament is homogeneous.
[0062] The first composition and the second composition are provided with such volume that when combined, the volume of the combined liquid medicine is acceptable for several single oral doses.Usually, the volume of the combined liquid medicine is between 1 to 150ml, preferably 20 to 100ml, more preferably 50 to 90ml, such as about 70ml.Therefore, the volume of the first and second compositions is selected to provide such a total volume of the combined liquid medicine.The volume of the combined medicine is suitable for providing 1 to 50 single doses, such as 5 to 20 single doses.Single dose includes 5 to 50mg, preferably 10 to 40mg.As will be apparent to those skilled in the art, the clinician will measure the appropriate dose of the combined liquid medicine and administer it to the patient in need.
[0063] In another embodiment, the present invention provides a kit comprising the first and second compositions, so that the two compositions are stored separately and combined immediately before use to form a combined liquid. The resulting combined liquid medicine preferably has a pH of 7.5 to 9.5, and the pH stability is maintained for at least 7 days.
[0064] The first and second compositions maintained separately can be stored for at least 12 months, and the active agent retains its activity for at least 12 months.
[0065] The kit may comprise a removable barrier between the two compositions. The removable barrier is configured to prevent contact between the two compositions, whereby removal of the removable barrier allows the two compositions to be combined immediately prior to administration to provide a combined solution. In a preferred embodiment, the barrier is a breakable membrane.
[0066] Optionally, the removable barrier may be reusable, as long as it separates the two compositions and can be removed so as to allow mixing of the two compositions. For example, the removable barrier may be two separate containers for the two compositions, having a removable opening such as a cap or lid. Alternatively, the removable barrier may have the characteristics of a single container containing the two compositions separated by the removable barrier. Preferably, the removable barrier is made of plastic or glass. More preferably, the removable barrier is made of amber high density polyethylene.
[0067] The pharmaceutical preparations of the present invention are provided for treating a variety of conditions such as gastritis, gastroesophageal reflux disease, dyspepsia, peptic ulcer disease, laryngopharyngeal reflux, gastric and duodenal ulcers and Zollinger-Ellison syndrome, thereby treating the conditions by proton pump inhibition. The pharmaceutical preparations of the present invention are suitable for use in adults and children.
[0068] In use, the clinician or patient mixes the first and second compositions to form a combined liquid, which is then orally administered directly to the patient.
[0069] The formulations and kits of the present invention combine a long shelf life with minimal degradation of the active substance, and a convenient and palatable dosage form for administration.
[0070] refer to Figure 1 Suitable dual compartment multi-dose packages for storing and mixing the compositions of the present invention include:
[0071] Cap with tamper evident tear strip
[0072] The cap (1) on the first compartment comprises means for applying pressure to the plunger (3) so as to partially rupture the breakable polymer membrane (4) of the stopper and transfer the solution into a container (6) having a second liquid composition (a diluent for the esomeprazole solution in an amount of 68 mL).
[0073] Tamper Evident Tear Strip (2)
[0074] The tamper-evident tear strip (2) ensures the overall integrity of the product until the time of application.
[0075] The first compartment consists of:
[0076] Plunger - First Container (3)
[0077] The plunger (3) is adapted to be loaded with a stopper (4) having a top flat surface, said stopper (4) containing a first composition of esomeprazole oral solution in an amount of 2 ml.
[0078] Plug (4)
[0079] The stopper (4) having a breakable polymer film is adapted to be inserted into the open bottle liner (5) from the lower end and into the cap (1) from the upper end.
[0080] The second compartment contains:
[0081] Open bottle lining (5)
[0082] Container - Second Container (6)
[0083] The second compartment is in the form of a container (6) provided with an open bottle liner (5) at the upper end, which contains a liquid diluent for the oral solution of esomeprazole in an amount of 68 ml. In the container (6), the two liquid compositions are mixed at the time of administration. Example
[0084] The following examples further illustrate the present invention:
[0085] Example 1 (emulsion) 20 mg / 10 ml, 70 ml:
[0086] First compartment:
[0087] Esomeprazole 0.140 g or 0.149 g as sodium salt in 2 ml DMSO solvent
[0088] Second compartment (68mL)
[0089]
[0090] method:
[0091] The hydrophilic phase and the hydrophobic phase were prepared separately under heating to 65°.
[0092] Potassium bicarbonate, sodium carbonate, sucralose, polysorbate 80 and simethicone emulsion were dissolved in water and heated to 65°C (hydrophilic phase).
[0093] Phosphatidylcholine, methylparaben and butylhydroxytoluene were dissolved in olive oil heated to 75° C. (lipophilic phase). Then sodium carboxymethylcellulose was dispersed.
[0094] The hydrophilic phase was dispersed in the lipophilic phase under high-speed homogenization at 1500-4000 rpm for 15 minutes.
[0095] Mixing and cooling were carried out using a propeller mixer at 80 rpm and under a negative pressure of 0.3 bar for at least 1 hour.
[0096] Flavor was added and mixed for an additional hour at 30° C. A stable emulsion was obtained.
[0097] The two compositions were stored in a two-compartment system, where the API in DMSO was contained in the first compartment (made of HDPE / PE / PP) and 68 ml of diluent was in the second compartment. The second compartment was made of HDPE or PET plastic and had a volume of 100 ml.
[0098] Combine and shake the two compositions immediately before first use. Measure out an appropriate volume of the combined preparation using, for example, a syringe or dosing spoon, and administer to the patient in need thereof.
[0099] Example 2 (emulsion) 20 mg / 10 ml, 70 ml:
[0100] First compartment:
[0101] Esomeprazole 0.140 g or 0.149 g as sodium salt, dissolved in 2 ml DMSO solvent
[0102] Second compartment: (68mL)
[0103]
[0104] The emulsion was prepared by a similar method to Example 1 - potassium bicarbonate, sodium carbonate, sucralose, sodium carboxymethylcellulose, PEG 40 hydrogenated castor oil and dimethicone emulsion formed the hydrophilic phase, and phosphatidylcholine, polyglyceryl-3 oleate, methylparaben and butylhydroxytoluene formed the lipophilic phase.
[0105] Example 3 (water-based solution) 20 mg / 10 ml, 70 ml:
[0106] First compartment:
[0107] Esomeprazole 0.140 g or 0.149 g as sodium salt, dissolved in 2 ml DMSO solvent
[0108] Second compartment: (68mL)
[0109]
[0110] method:
[0111] Potassium bicarbonate and sodium carbonate salts were dissolved in 2 / 3 of the water. Subsequently, benzalkonium chloride was dissolved in a propeller mixer at 80 rpm with a mixing time of 15 minutes.
[0112] Sodium chloride, maltodextrin and simethicone emulsion were dissolved sequentially in a propeller mixer at 80 rpm with an intermediate mixing time of 15 minutes.
[0113] After complete dissolution, cyclodextrin and sweetener were dissolved sequentially with an intermediate mixing time of 15 minutes.The polymer was added in 3 portions in a propeller mixer at a higher stirrer speed (at least 100 rpm).
[0114] The polymer was hydrated for 1 hour, and after full hydration, the remaining flavor was added and mixed for an additional 30 minutes with a propeller mixer operating at at least 100 rpm.
[0115] The pH was adjusted to 9.0-9.5 with 1 M NaOH solution, and the volume was adjusted to 68 mL with water.
[0116] The two compositions are stored in a two-compartment system, wherein the API in DMSO is contained in the first compartment (made of HDPE / PE / PP) and 68 ml of diluent is in the second compartment (aqueous solution). The second compartment is made of HDPE plastic, PET or (preferably) amber glass and has a volume of 120-130 ml.
[0117] Combine and shake the two compositions immediately before first use. Measure out an appropriate volume of the combined preparation, for example, using a syringe or dosing cup, and administer to the patient in need thereof.
[0118] Example 4 (water-based solution) 20 mg / 10 ml, 70 ml:
[0119] First compartment:
[0120] Esomeprazole 0.140 g or 0.149 g as sodium salt, dissolved in 2 ml DMSO solvent
[0121] Second compartment: (68mL)
[0122]
[0123]
[0124] This solution was prepared by a method similar to Example 4.
[0125] Example 5 (water-based solution) 20 mg / 10 ml, 70 ml:
[0126] First compartment:
[0127] Esomeprazole 0.140 g or 0.149 g as sodium salt in 2 ml DMSO solvent Second compartment: (68 mL)
[0128]
[0129] This solution was prepared by a method similar to Example 4.
[0130] Example 6 (water-based solution) 20 mg / 10 ml, 70 ml:
[0131] First compartment:
[0132] Esomeprazole 0.140 g or 0.149 g as sodium salt in 2 ml DMSO solvent Second compartment: (68 mL)
[0133]
[0134] 1: Ph.Eur. Current edition of the European Pharmacopoeia;
[0135] 2: USP current edition of the United States Pharmacopoeia
[0136] 3: Regulation (EC) No. 1334 / 2008
[0137] Example 7 (oil-in-water oral emulsion) 20 mg / 10 ml, 70 ml:
[0138] First compartment:
[0139] Esomeprazole 0.140 g or 0.149 g as sodium salt in 2 ml DMSO solvent Second compartment: (68 mL)
[0140]
[0141]
[0142] 1: Ph.Eur. Current edition of the European Pharmacopoeia;
[0143] 2: USP current edition of the United States Pharmacopoeia
[0144] 3: Regulation (EC) No. 1334 / 2008
[0145] Example 8 (oil-in-water oral emulsion) 20 mg / 10 ml, 70 ml:
[0146] First compartment:
[0147] Esomeprazole 0.140 g or 0.149 g as sodium salt in 2 ml DMSO solvent Second compartment: (68 mL)
[0148]
[0149]
[0150] 1: Ph.Eur. Current edition of the European Pharmacopoeia;
[0151] 2: USP current edition of the United States Pharmacopoeia
[0152] 3: Regulation (EC) No. 1334 / 2008
[0153] Example 9 - Stability Study
[0154] Stability results of esomeprazole sodium dissolved in DMSO stored at 25°C:
[0155]
[0156]
[0157]
[0158] Keywords:
[0159] Imp D:Omeprazole Impurity D: RRT: relative retention time.
[0160] Example 10 - Palatability Study
[0161] The aqueous emulsion and the combination drug of Example 2 were evaluated as palatable by a panel of volunteers.
Claims
1. A pharmaceutical preparation comprising: a first composition which is a non-aqueous liquid comprising a substituted benzimidazole selected from omeprazole, esomeprazole and pharmaceutically acceptable salts thereof, and a polar aprotic solvent; and a second composition which is an aqueous liquid comprising a base; in, The first and second compositions are configured to be combined prior to use to provide a combined liquid medicament having a pH in the range between 7.5 and 9.
5.
2. A pharmaceutical formulation according to claim 1, wherein the second composition comprises one or more pharmaceutically acceptable excipients and / or adjuvants, preferably selected from the group consisting of viscosity enhancers, dispersants, emulsifiers, stabilizers, preservatives, defoamers, flavoring agents, antioxidants, chelating agents and tonicity regulators.
3. A pharmaceutical formulation according to any preceding claim, wherein after combining the first and second compositions, the substituted benzimidazole has a concentration of between 0.5 mg / ml and 5 mg / ml.
4. A pharmaceutical formulation according to any preceding claim, wherein the substituted benzimidazole is dissolved in a polar aprotic solvent.
5. A pharmaceutical formulation according to any preceding claim, wherein the polar aprotic solvent is an organic sulfur compound, preferably dimethyl sulfoxide.
6. A pharmaceutical formulation according to any preceding claim, wherein the second composition is an emulsion or a solution.
7. The pharmaceutical formulation according to claim 6, wherein the second composition is a water-in-oil (w / o) emulsion further comprising an emulsifier system and a lipophilic phase.
8. The pharmaceutical formulation according to claim 6, wherein the second composition is an oil-in-water (o / w) emulsion further comprising an emulsifier system and a lipophilic phase.
9. The pharmaceutical formulation according to claim 7 or 8, wherein the emulsifier system comprises an emulsifier with HLB<8, preferably sorbitan monooleate, phosphatidylcholine, polyglyceryl-3 oleate or a combination thereof.
10. The pharmaceutical formulation according to claim 8 or 9, wherein the emulsifier system comprises an emulsifier with HLB>8, preferably polysorbate 80, polyoxyethylene 40, hydrogenated castor oil or a combination thereof.
11. Pharmaceutical formulation according to any one of claims 7 to 10, wherein the lipophilic phase is selected from medium-chain and long-chain triglycerides, preferably olive oil or caprylic capric triglyceride.
12. A pharmaceutical formulation according to any one of claims 7 to 11, wherein the lipophilic phase is present in an amount of less than 20% w / w based on the weight of the second composition.
13. Pharmaceutical formulation according to any one of claims 7 to 12, wherein the emulsion additionally comprises a waxy compound, preferably glyceryl monostearate, cetearyl alcohol, glyceryl disbehenate or a combination thereof.
14. A pharmaceutical formulation according to any preceding claim, wherein the base is selected from metal carbonates and metal bicarbonates or combinations thereof, preferably sodium carbonate, sodium bicarbonate or potassium bicarbonate or combinations thereof.
15. A pharmaceutical formulation according to any preceding claim comprising a taste masking agent, preferably selected from cyclodextrin, maltodextrin and sodium chloride or a combination thereof.
16. A pharmaceutical formulation according to any preceding claim, comprising a viscosity increasing agent, preferably selected from cellulose based polymers, xanthan gum, sodium alginate and acrylic polymers or combinations thereof.
17. A pharmaceutical formulation according to any preceding claim, wherein the first and / or second composition comprises one or more additional components selected from the group of stabilizers, wetting agents, antifoaming agents, preservatives, antimicrobials, flavoring agents and sweeteners.
18. A pharmaceutical formulation according to any preceding claim, wherein the formulation is a multi-dose formulation.
19. A pharmaceutical formulation according to any preceding claim, wherein the formulation is stable at a temperature of about 2°C to about 25°C for up to one week following combination of the first and second compositions.
20. A pharmaceutical composition according to any preceding claim for use in the treatment of a condition selected from the group consisting of gastritis, gastroesophageal reflux disease, dyspepsia, peptic ulcer disease, laryngopharyngeal reflux, gastric and duodenal ulcers and Zollinger-Ellison syndrome.
21. A kit comprising: a first compartment containing a first composition as defined in any one of claims 1 to 19; a second compartment containing a second composition as defined in any one of claims 1 to 19; and in, The first and second containers are adapted to allow liquid communication therebetween upon activation to form a combined liquid medicament as defined in any one of claims 1 to 19.
22. A kit as defined in claim 21, wherein the first composition is present in an amount of 1 to 5 mL, preferably about 2 mL.
23. A kit as defined in claim 21 or 22, wherein the second composition is present in an amount of 25 to 100 mL, preferably about 68 mL.
